Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070950 | 0.86 | TSHR (0.55) | TSHRMAPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL535352 | 0.85 | MAPK1 (0.53) | TSHRMAPK1KMT2AMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3554884 | 0.84 | MAPK1 (0.52) | TSHRMAPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL2949639 | 0.83 | TSHR (0.60) | TSHRMAPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL67864 | 0.83 | MAPK1 (0.60) | TSHRMAPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL27273104 | 0.83 | MAPK1 (0.60) | TSHRMAPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL68181 | 0.81 | TSHR (0.58) | TSHRMAPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL68713 | 0.81 | TSHR (0.58) | TSHRMAPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL6377973 | 0.81 | MAPK1 (0.58) | TSHRMAPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL9191570 | 0.81 | MAPK1 (0.58) | TSHRMAPK1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20140057928-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-8598183-B2 | Solid state forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-03 | — | — | US | disclosed |
| US-20130288957-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130261050-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20130261134-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| WO-2013147750-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013147749-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013149147-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| EP-2621495-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | Boehringer Ingelheim International GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| EP-1018333-B1 | Use of cationic monobenzene nitroanilines for dyeing keratin fibres , compositions and dyeing process | OREAL (FR) | 2006-03-01 | — | — | EP | disclosed |
| EP-1018508-B1 | Cationic monobenzenic nitrophenylene diamines, their use for dyeing keratinic fibres, dye compositions containing them and dye processes | OREAL (FR) | 2005-05-04 | — | — | EP | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1453516-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
| WO-2003032994-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
| US-6478827-B1 | Use of cationic monobenzene nitroanilines in the dyeing of keratinous fibers, dyeing compositions and dyeing processes | L'ORéAL S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-6464731-B1 | 1-(3-(4-AMINO-2-CHLORO-5-NITROPHENYLAMINO)PROPYL)-3-METHYL-3H -IMIDAZOL-1-IUM BROMIDE USED AS DIRECT HAIR DYES; SOLUBILITY AND PHOTOSTABILITY | L'OREAL S.A. (FR) | 2002-10-15 | — | — | US | disclosed |
| EP-1018508-A1 | Cationic monobenzenic nitrophenylene diamines, their use for dyeing keratinic fibres, dye compositions containing them and dye processes | L'OREAL (FR) | 2000-07-12 | — | — | EP | disclosed |
| EP-1018333-A2 | Use of cationic monobenzene nitroanilines for dyeing keratin fibres , compositions and dyeing process | L'OREAL (FR) | 2000-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | TSHR 3558/4885MAPK1 2993/4885KMT2A 2987/4885 |
| US-20130288957-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | IL36G, IL17A, IL6ST | TSHR 2633/4885MAPK1 2417/4885KMT2A 4074/4885 |
| US-20130261050-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | SLC10A1, HAVCR2, GOT2 | TSHR 3874/4885MAPK1 4338/4885KMT2A 3755/4885 |
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | TSHR 2452/4885MAPK1 1207/4885KMT2A 4026/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | TSHR 2038/4885MAPK1 1279/4885KMT2A 4480/4885 |
| US-20130261134-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | SLC10A1, HAVCR2, ABL1 | TSHR 4732/4885MAPK1 758/4885KMT2A 1236/4885 |
| US-20140057928-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | TSHR 4574/4885MAPK1 455/4885KMT2A 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.